The angiogenic activity of ascites in the course of ovarian cancer as a marker of disease progression

Disease Markers

Volumn 2014, Issue , 2014, Pages

  Gawrychowski, Krzysztof ^a   Szewczyk, Grzegorz ^b,c   Skopińska Rózewska, Ewa ^c   Małecki, Maciej ^b,c   Barcz, Ewa ^c   Kamiński, Paweł ^c   Miedzińska Maciejewska, Magdalena ^d   Śmiertka, Wacław ^e   Szukiewicz, Dariusz ^c   Skopiński, Piotr ^c  

^a Medicover Hospital   (Poland)

^b INSTITUTE OF MOTHER AND CHILD   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d Holy Family Clinic of Gynecology and Obstetrics in Warsaw   (Poland)

^e INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; INTERLEUKIN 8; TUMOR MARKER; VASCULOTROPIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; ANGIOGENESIS; ANGIOGENESIS INDEX; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; ASCITES; CANCER CELL CULTURE; CANCER GROWTH; CANCER STAGING; CELL ISOLATION; CELL SUSPENSION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; GRANULOCYTE; HUMAN; HUMAN CELL; LAPAROTOMY; LYMPHOCYTE; MACROPHAGE; MESOTHELIUM CELL; MIDDLE AGED; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; OVARY CANCER; PARACENTESIS; PERITONEAL FLUID; PRIORITY JOURNAL; SCORING SYSTEM; VERY ELDERLY; ANIMAL; ASCITES FLUID; BAGG ALBINO MOUSE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); OVARY TUMOR; PATHOLOGY; PHYSIOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ASCITIC FLUID; DISEASE PROGRESSION; FEMALE; HUMANS; INTERLEUKIN-8; MICE; MICE, INBRED BALB C; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84893764205     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2014/683757     Document Type: Article

References (19)

1. Makris A., Ryan K. J., Yasumizu T., The nonluteal porcine ovary as a source of angiogenic activity. Endocrinology 1984 115 5 1672 1677 2-s2.0-0021690974 (Pubitemid 15206578)
2. Kamat B. R., Brown L. F., Manseau E. J., Senger D. R., Dvorak H. F., Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells: role in corpus luteum development. American Journal of Pathology 1995 146 1 157 165 2-s2.0-0028982229
3. Ioannides C. G., Platsoucas C. D., Rashed S., Wharton J. T., Edwards C. L., Freedman R. S., Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites. Cancer Research 1991 51 16 4257 4265 2-s2.0-0025940346
4. Sheid B., Angiogenic effects of macrophages isolated from ascitic fluid aspirated from women with advanced ovarian cancer. Cancer Letters 1992 62 2 153 158 2-s2.0-0026525042 10.1016/0304-3835(92)90186-Y
5. Nagy J. A., Masse E. M., Herzberg K. T., Meyers M. S., Yeo K.-T., Yeo-T. K., Sioussat T. M., Dvorak H. F., Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Research 1995 55 2 360 368 2-s2.0-0028834106
6. van Diest P. J., Zevering J. P., Zevering L. C., Baak J. P. A., Prognostic value of microvessel quantitation in cisplatin treated FIGO 3 and 4 ovarian cancer patients. Pathology Research and Practice 1995 191 1 25 30 2-s2.0-0028956630
7. Biselli-Chicote P. M., Oliveira A. R., Pavarino E. C., Goloni-Bertollo E. M., VEGF gene alternative splicing: pro- and anti-angiogenic isoforms in cancer. Journal of Cancer Research and Clinical Oncology 2012 138 3 363 370 2-s2.0-84859717742 10.1007/s00432-011-1073-2
8. Koch S., Claesson-Welsh L., Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harbor Perspectives in Medicine 2012 2 7 10.1101/cshperspect.a006502 006502
9. Strieter R. M., Polverini P. J., Arenberg D. A., Kunkel S. L., The role of CXC chemokines as regulators of angiogenesis. Shock 1995 4 3 155 160 2-s2.0-0029363531
10. Koch A. E., Polverini P. J., Kunkel S. L., Harlow L. A., DiPietro L. A., Elner V. M., Elner S. G., Strieter R. M., Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992 258 5089 1798 1801 2-s2.0-0027097806 (Pubitemid 23087348)
11. Szukiewicz D., Pyzlak M., Klimkiewicz J., Szewczyk G., Maslinska D., Mast cell-derived interleukin-8 may be involved in the ovarian mechanisms of follicle growth and ovulation. Inflammation Research 2007 56 1 S35 S36 2-s2.0-34548297778 10.1007/s00011-006-0517-7 (Pubitemid 47345689)
12. Sidky Y. A., Auerbach R., Lymphocyte induced angiogenesis: a quantitative and sensitive assay of the graft vs. host reaction. Journal of Experimental Medicine 1975 141 5 1084 1100 2-s2.0-0016813630
13. Li C. Y., Shan S., Huang Q., Braun R. D., Lanzen J., Hu K., Lin P., Dewhirst M. W., Initial stages of tumor cell-induced angiogenesis: Evaluation via skin window chambers in rodent models. Journal of the National Cancer Institute 2000 92 17 1445 1446 2-s2.0-0034612770
14. Ziogas A. C., Gavalas N. G., Tsiatas M., Tsitsilonis O., Politi E., Terpos E., Rodolakis A., Vlahos G., Thomakos N., Haidopoulos D., Antsaklis A., Dimopoulos M. A., Bamias A., VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor type 2. International Journal of Cancer 2012 130 4 857 864 2-s2.0-83955164291 10.1002/ijc.26094
15. Koch A. E., Polverini P. J., Kunkel S. L., Harlow L. A., DiPietro L. A., Elner V. M., Elner S. G., Strieter R. M., Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992 258 5089 1798 1801 2-s2.0-0027097806 (Pubitemid 23087348)
16. Matte I., Lane D., Laplante C., Rancourt C., Piché A., Profiling of cytokines in human epithelial ovarian cancer ascites. American Journal of Cancer Research 2012 2 5 566 580
17. Lane D., Matte I., Rancourt C., Piché A., Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer 2011 11, article 210 2-s2.0-79957466111 10.1186/1471-2407-11-210
18. Perren T. J., Swart A. M., Pfisterer J., Ledermann J. A., Pujade-Lauraine E., Kristensen G., Carey M. S., Beale P., Cervantes A., Kurzeder C., Du Bois A., Sehouli J., Kimmig R., Staäle A., Collinson F., Essapen S., Gourley C., Lortholary A., Selle F., Mirza M. R., Leminen A., Plante M., Stark D., Qian W., Parmar M. K. B., Oza A. M., A phase 3 trial of bevacizumab in ovarian cancer. The New England Journal of Medicine 2011 365 26 2484 2496 2-s2.0-84855466019 10.1056/NEJMoa1103799
19. Aghajanian C., Blank S. V., Goff B. A., Judson P. L., Teneriello M. G., Husain A., Sovak M. A., Yi J., Nycum L. R., OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. Journal of Clinical Oncology 2012 30 17 2039 2045 10.1200/JCO.2012.42.0505